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Objective: Lung transplantation is limited by the shortage of suitable donors. To
overcome this problem, many programs have begun to use marginal or extended
donors after reports suggesting equivalent outcomes with no additional risk. As our
use of extended donor lungs increased and our recipient selection criteria expanded,
we believed it was appropriate to reevaluate outcomes with extended donor lungs
compared with outcomes with standard donor lungs and recipients outside of the
currently accepted guidelines.
Methods: We performed a retrospective review of 128 consecutive lung or heart-
lung transplants from January 1, 1997, to June 30, 2000. The primary endpoint was
30-day mortality. Donors were considered extended if any one of the following cri-
teria were met: age greater than 55 years, smoking longer than 20 pack-years, pres-
ence of chest radiographic film infiltrate, PO2 of less than 300 mm Hg, or purulent
secretions on bronchoscopy. Guideline and nonguideline recipients were defined on
the basis of previously published criteria.
Results: Of a total of 123 donors, 63 (51%) were extended. Forty-eight donors failed
1 criterion, 10 failed 2 criteria, and 5 failed 3 criteria. One hundred twenty-eight
transplants were performed. The 30-day mortality for the standard donor group was
4 (6.2%) of 65 versus 11 (17.5%) of 63 for the extended donor group (P = .047).
Conclusions: Although many extended donor lungs will result in acceptable post-
operative function, caution needs to be exercised in the uses of certain extended
donor lungs because there seems to be an increased early mortality rate in that
group of recipients. Nonguideline recipients appear to have acceptable early mor-
tality, except when they received extended donor lungs.
Donor organ availability continues to be a serious problem facing allsolid-organ transplants and is particularly serious with regard tolung transplantation.1 The demand for donor lungs clearly exceedsthe supply, and patients continue to die while on waiting lists beforea suitable organ becomes available. The donor lung may becomeinjured by the mechanism of death, fluid resuscitation, neurogenic
pulmonary edema, aspiration pneumonia, or nosocomial pneumonia. Only about 20%
of multiorgan donors ultimately have lungs that are suitable for lung transplantation
according to currently accepted criteria. These rigid criteria were instituted in the mid-
1980s during the early development of clinical lung transplantation.2
A number of options are available to improve donor availability and to reduce
mortality on the waiting list. Epoprostenol (prostacyclin) infusion may prolong sur-
vival in patients with primary pulmonary hypertension. Lung volume reduction may
provide an alternative or bridge to lung transplantation for select patients with
emphysema. A priority system for allocating organs will help the neediest recipients
receive transplants before more stable patients on the waiting list. Such a priority
system may improve overall survival on the waiting list for the entire group of
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patients. Live donors and non–heart-beating lung donors
are other options. Social awareness and political or legisla-
tive changes have the potential to significantly improve the
donor pool. Unfortunately, many of these and other options
simply have not alleviated the current donor shortage.
To overcome this donor shortage, some programs have
initiated the use of marginal or extended donors after
reports suggesting equivalent outcomes with respect to
early morbidity and mortality.3-5 Others have demonstrated
equivalent 1-year pulmonary function and survival with
extended donor lungs.6 As our own program’s use of
extended donor lungs increased and our recipient selection
criteria expanded, we believed it was appropriate to evalu-
ate our outcomes with these organs compared with out-
comes with standard or ideal donor lungs and to compare
guideline and nonguideline recipients.
Methods
Between January 1, 1997, and June 30, 2000, data were collected
on 128 consecutive lung or heart-lung transplants at the Toronto
General Hospital. A retrospective analysis was then performed.
Donors were divided retrospectively into 1 of 2 groups: standard
or extended. Donors were considered extended if any 1 of the fol-
lowing criteria were met: age greater than 55 years, smoking his-
tory greater than 20 pack-years, presence of chest radiographic
infiltrate, PO2 of less than 300 mm Hg on 100% oxygen with 5 cm
H2O positive end-expiratory pressure, or purulent secretions on
bronchoscopy. Standard donors fulfilled all of the previously
accepted criteria for lung retrieval (ie, age <55 years, smoking <20
pack-years, clear chest radiograph, PO2 >300 mm Hg, and clear
bronchoscopy).2 Donors were assessed by either the lung trans-
plant fellow or the staff lung transplant surgeon from our program.
Donor arterial PO2 was based on the final donor PO2 measure-
ment before flushing the lungs. Although some donors had initial
PO2 values of less than 300 mm Hg, after donor resuscitation and
management, there were no final PO2 values of less than 300 mm
Hg. Four donors had initial PO2 values of less than 300 mm Hg.
Mucoid secretions on bronchoscopy that could be suctioned clear
were considered normal, and those donors were placed into the
standard donor group. Only donors with truly purulent secretions
were placed into the extended donor group.
The multiorgan donor was managed to maintain euvolemia and
to avoid excessive fluid administration. We routinely give 2 g of
intravenous methylprednisolone (Solu-Medrol; Upjohn, Don
Mills, Ontario, Canada) after initial contact with the donor hospi-
tal. The lung procurement follows standard procedures, with an
antegrade flush through the main pulmonary artery; however, we
use a low potassium dextran solution (Perfadex; Vitrolife,
Uppsala, Sweden).7
Guideline or nonguideline recipients were defined retrospec-
tively by using the “International Guidelines for the Selection of
Lung Transplant Candidates.”8 A subgroup analysis was finally
performed, looking at combinations of (1) standard donor plus
guideline recipient, (2) standard donor plus nonguideline recipi-
ent, (3) extended donor plus guideline recipient, and (4) extended
donor plus nonguideline recipient.
The primary end point was 30-day mortality. Secondary end
points included 90-day mortality, the ratio of PO2 to fraction of
inspired oxygen (FIO2) on arrival in the intensive care unit (ICU),
and ICU length of stay.
Statistical analysis was performed with the SigmaStat software
package (Jandel Scientific, San Rafael, Calif). Comparison
between groups was done with the unpaired t test for continuous
variables or the χ2 test for categorical variables. Multiple table
comparisons were performed with the Mantel-Haentzel test. Data
are reported as means ± SD.
Results
For 128 lung or heart-lung transplants, we had 123 donors,
of whom 63 (51%) were extended donors. Table 1 outlines
the criteria and number for the extended group. There were
no donors with a final PO2 of less than 300 mm Hg. Four
donors had an initial PO2 of less than 300 mm Hg, but no
deaths occurred in this group. Forty-eight of the 63
extended donors failed to satisfy only 1 criterion. Ten
extended donors failed to satisfy 2 criteria, and 5 extended
donors failed to satisfy 3 criteria.
TABLE 1. Criteria used to define extended donors
Smoking Purulent
Age >55 y >20 pack-years CXR infiltrate PO2 <300 mm Hg bronchoscopic findings
Extended donor (n = 63) 9 26 41 0 8
CXR, Chest radiograph.
TABLE 2. Donor characteristics
Standard donor Extended donor
(n = 60) (n = 63)
Donor age (y) 32 ± 14 44 ± 16*
Duration of mechanical ventilation (h) 44 ± 39 60 ± 46*
Ventilation >4 d 2/60 11/63*
Cause of death (n)
ICH/SAH 32 40
Head injury 28 23
Total donor lung ischemic time (h) 5.3 ± 1.3 5.5 ± 1.7
ICH, Intracerebral hemorrhage; SAH, subarachnoid hemorrhage.
*P < .05.
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Table 2 compares several clinical variables between the
2 groups of donors. The mean donor age was older in
the extended donor group (44 vs 32 years, P = .0001). The
duration of mechanical ventilation before retrieval was also
significantly longer in the extended donor group (60 vs 44
hours, P = .025). In addition, the proportion of donors ven-
tilated for greater than 4 days was higher in the extended
donor group (P = .024). Cause of death was similar between
groups (P = .337). The total ischemic time of the donor lung
or lungs was not different between groups (P = .399).
There were 18 single lung transplants, 107 bilateral lung
transplants, and 3 heart-lung transplants. Table 3 shows the
recipient characteristics. All 3 heart-lung recipients received
standard donor lungs. One of the bilateral lung transplants
was a split left donor lung lobar transplant in a small patient
with pulmonary fibrosis (extended donor). One bilateral
lung transplant was combined with a liver transplant for cys-
tic fibrosis (standard donor), and 1 single lung donor also
received a coronary artery bypass (standard donor). One
bilateral lung transplant was a retransplant for chronic rejec-
tion in a patient with cystic fibrosis (standard donor). One
bilateral lung transplant was a left upper lobe transplant with
a complete right lung transplant (extended donor).
Cardiopulmonary bypass was used in 16 (25%) of 65
recipients from standard donors and 24 (38%) of 63 recipients
from extended donors (P = .172). Our policy is to use bypass
electively for patients with primary pulmonary hypertension
or Eisenmenger syndrome. We also used cardiopulmonary
bypass for patients with prior pneumonectomies and for heart-
lung transplantation. Collectively, these were considered
planned pump cases. All other situations were considered
unplanned pump cases. Cardiopulmonary bypass was used
selectively for all other indications, depending on intraopera-
tive factors. There were 7 (11%) of 65 unplanned pump cases
in the standard donor group and 13 (21%) of 63 unplanned
pump cases in the extended donor group (P = .196).
The only recipient factor that was significantly different
between the 2 groups was the sex distribution. There were
more male patients (63%) in the standard donor group and
more female patients (63%) in the extended donor group (P
= .005). Recipient age and diagnosis was not different
between groups.
Table 4 shows the number of nonguideline recipients.
Twenty-nine percent were nonguideline recipients, mostly
because of older age or colonization with Burkholderia
cepacia.
Table 5 shows the results of 30-day mortality, 90-day
mortality, first PO2/FIO2 ratio on arrival in the ICU, and ICU
length of stay. The 30-day mortality rate for the extended
donor group was significantly higher than that for the stand-
ard donor group (17.5% vs 6.2%, P = .047). The 90-day
mortality was 5 (7.7%) of 65 in the standard group and 14
(22.2%) of 63 in the extended group (P = .0391). There was
no significant difference between groups with respect to
TABLE 3. Recipient characteristics
Standard donor Extended donor
Age (y) 47 46
Age ≥65 y (n) 8 4
Sex (M/F) 41/24 23/40*
Underlying diagnosis (n)
COPD 16 22
CF
B cepacia negative 9 6
B cepacia positive 5 9
IPF 17 12
Pulmonary hypertension 10 6
Other 8 8
Type of transplant (BLT/SLT/HLT) 50/12/3 57/6/0
COPD, Chronic obstructive pulmonary disease; CF, cystic fibrosis; IPF,
idiopathic pulmonary fibrosis; BLT, bilateral lung transplant; SLT, single
lung transplant; HLT, heart-lung transplant.
*P < .05.
TABLE 5. Recipient outcome: Standard versus extended
donors
Standard donor Extended donor
30-Day mortality 6.2% (4/65) 17.5% (11/63)*
90-Day mortality 7.7% (5/65) 22.2% (14/63)*
First PO2/FIO2 ratio (mm Hg) 374 ± 143 358 ± 131
ICU length of stay (d) 10.5 ± 16.0 8.4 ± 12.5
*P < .05.
TABLE 4. Nonguideline recipients (37/128 [29%])
Criteria No.
Age 19
B cepacia 14
CABG + transplant 1
Retransplant 1
Malignancy (BAC) 1
Liver-lung transplant 1
BAC, Bronchoalveolar carcinoma; CABG, coronary artery bypass graft.
TABLE 6. Recipient outcome: Subgroups 30-day mortality
30-Day mortality
Standard donor + guideline recipient 6.5% (3/46)
Standard donor + nonguideline recipient 5.3% (1/19)
Extended donor + guideline recipient 15.6% (7/45)
Extended donor + nonguideline recipient 22.2% (4/18)
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first PO2/FIO2 ratio on arrival in the ICU (P = .4223) and
ICU length of stay (P = .496).
There was no apparent difference in the 30-day mortal-
ity between guideline (11%) and nonguideline (13.5%)
recipients (P = .208). Table 6 shows the 30-day mortality
for the combination of donors and recipients. None of the
subgroup comparisons was statistically significantly differ-
ent, but the relative risk of death for standard donor plus
nonguideline recipient versus marginal donor plus
nonguideline recipient was 1.92 (P = .18).
A detailed retrospective analysis was carried out on each
of the 15 deaths. Although admittedly subjective, we
believed that our personal involvement in each case allowed
assignment of cause of death to be either definitely donor
related, definitely donor unrelated, or possibly donor
related. Four deaths occurred in the standard donor group,
and 11 deaths occurred in the marginal donor group (Tables
7 and 8). Our consensus opinion was that none of the 4
deaths in the standard donor group was likely related to the
donor. Patient 1 died of a perioperative myocardial infarc-
tion with unrecognized coronary disease. Patient 2 had a
myocardial infarction on the operating table and could not
be weaned from cardiopulmonary bypass. This patient also
had unrecognized coronary disease. These 2 deaths resulted
in our current policy of performing routine heart catheteri-
zation in all patients over the age of 50 years. Patient 3 was
doing well postoperatively and died of a sudden massive
pulmonary embolism. Patient 4 was doing extremely well
and was about to be discharged home when he had an unex-
pected cardiac arrest, presumably caused by an arrhythmia,
on postoperative day 12, resulting in death.
Our joint assessment was that 5 of the 11 deaths in the
marginal donor group were explained by factors other than
the quality of the donor lung (Table 8). Patient 5 died with
nosocomial Serratia species–induced pneumonia (non-
donor source). Patients 6 and 7 had cystic fibrosis and died
of B cepacia–induced sepsis, and patient 9 died of a noso-
comial Pseudomonas species–induced pneumonia (non-
donor source). Patient 12 had a split left lung-lobar
transplant and died of reperfusion injury. We believe that
this was due to hyperperfusion through too small a vascular
bed, as has been seen after living-donor lobar transplanta-
TABLE 7. Standard donor deaths within 30 days (n = 4)
Donor-related
Patient No. Age (y) Sex Diagnosis Cause of death Date of death (d) Extended criteria death?
1 54 M α1 CAD/CHF 1 Standard No
2 52 F IPF Intraoperative 0 Standard No
arrest/CAD
3 55 F IPF PE 4 Standard No
4 65 M α1 Cardiac arrest 12 Standard No
α1, α1-Antitrypsin deficiency; CAD, coronary artery disease; CHF, congestive heart failure; IPF, idiopathic pulmonary fibrosis.
TABLE 8. Extended donor deaths within 30 days (n = 11)
Donor-related
Patient No. Age Sex Diagnosis Cause of death Date of death (d) Extended criteria death?
5 38 M PPH Sepsis, Serratia species 14 CXR No
6 33 M CF, B cepacia Sepsis 9 Age No
7 42 F CF, B cepacia Sepsis 18 CXR No
8 27 M CF, B cepacia Intraoperative arrest 10 CXR, PB Yes
9 55 F Sjogren syndrome Sepsis, Pseudomonas species 2 Smoke No
10 45 M IPF Reperfusion injury (right SLTx) 7 CXR Yes
11 23 F CF Intraoperative arrest, 11 PB Yes
brain death
12 45 F IPF Reperfusion injury 1 CXR No
13 64 M IPF Cardiogenic shock 9 CXR Yes
14 43 F PPH Reperfusion injury 1 CXR, smoke Yes
15 29 F COPD Reperfusion injury 2 CXR, PB Yes
PPH, Primary pulmonary hypertension; CXR, chest radiographic infiltrate; CF, cystic fibrosis; PB, purulent secretion on bronchoscopy; IPF, idiopathic pul-
monary fibrosis; smoke, >20 pack-years smoking history; age, donor age >55 years.
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tion. The right lung from the same donor was simultane-
ously implanted into another recipient without complica-
tion. The donor radiograph only had mild basal atelectasis
that was cleared by the time of procurement. Therefore, we
have not assigned this death to the quality of the donor lung.
The remaining 6 of 11 extended donor group deaths were
believed to be at least partially related to the quality of the
donor lung. Thus, 0 of 65 standard donor–related deaths and
6 of 63 extended donor–related deaths remain statistically
significant (P = .033).
The cause of death in the 6 extended donor lung recipi-
ents whose death was believed to be possibly related to the
quality of the donor lungs are as follows (Table 8). Patient 8
had an intraoperative cardiac arrest preceded by hemody-
namic instability after the left lung graft had been implanted.
Emergency cardiopulmonary bypass was instituted, but a
combination of cardiac and pulmonary problems ultimately
resulted in death on postoperative day 10. Patient 10 had a
right single lung transplant for idiopathic pulmonary fibro-
sis. The donor had an infiltrate-contusion in the left upper
lobe related to a motor vehicle accident, and we elected to
transplant just the right lung. There was hemodynamic insta-
bility while the native right lung was being mobilized; car-
diopulmonary bypass was instituted, and the case was
completed. The patient had severe reperfusion injury and
died on postoperative day 7. Patient 11 had sudden cardiac
arrest intraoperatively shortly after reperfusion of the first
implanted lung. Open cardiac massage and cardiopulmonary
bypass were instituted, but the patient ultimately had pro-
found neurologic injury and died on postoperative day 11.
Patient 13 underwent transplantation with the aid of car-
diopulmonary bypass. Gas exchange was impaired after
weaning from bypass; the patient had ventricular fibrillation
and was placed back on bypass. He was weaned a second
time, and the chest was closed when hypotension and ven-
tricular fibrillation again developed. Once again, he was
placed back on bypass. Ultimately, he was weaned with the
aid of an intra-aortic balloon pump. He died on postopera-
tive day 9 of cardiogenic shock and acute lung injury. Patient
14 had severe reperfusion injury immediately and died on
postoperative day 1. Patient 15’s donor had a motor vehicle
accident and had received a massive blood transfusion for a
retroperitoneal hematoma. The recipient had severe reperfu-
sion injury and died on postoperative day 2.
There were 3 deaths among 9 patients with cystic fibro-
sis and positive results for B cepacia in the extended donor
group and no deaths in 5 patients with B cepacia in the
standard group. Because B cepacia is an independent risk
factor for posttransplant mortality, we compared the pro-
portion of patients with B cepacia in each group to confirm
that they were evenly distributed and found that to be the
case. There were 5 of 65 patients with B cepacia in the stan-
dard group and 9 of 63 in the extended group (P = .346).
Discussion
We converted to using low-potassium dextran solution as
our lung preservation solution in 1997 after observing supe-
rior results compared with those obtained with modified
Euro-Collins solution.7 At the same time, our use of
extended donor lungs significantly increased compared
with in previous years, while reports were emerging in the
literature suggesting equivalent outcomes with extended
donor lungs compared with outcomes with standard donor
lungs.3,4 It was our impression that we had room to extend
both our donor and recipient criteria. Before analyzing
these data, our clinical impression was that extended donors
did not increase early mortality.
Kron and colleagues3 reported the first series of lung
transplants using marginal or extended donor lungs in 1993.
They evaluated 11 extended donors and used 10, which
amounted to 35% of the total lungs transplanted. One of
their 10 extended donor transplant recipients died, for an
early mortality rate of 10% in that group. All of their
extended donors had been on a ventilator for less than 2
days, and all secretions on bronchoscopy could be easily
cleared by suctioning. The mean duration of ventilation in
our extended donor group was 60 hours, and 17% of those
donors were ventilated for greater than 4 days before
retrieval. This prolonged period in the ICU puts the donor at
greater risk of nosocomial pneumonia and fluid overload
and may partly contribute to the increased early mortality in
the extended donor group in our study.
The 1995 report from the Washington University group9
is the largest and most detailed series looking at the use of
extended donor lungs. They had a total of 133 transplants,
33% of which were performed with extended donors. The
majority of their extended donors were defined as such
because of the presence of chest radiographic infiltrates. The
30-day mortality was 3.4% in the standard donor group and
0% in the extended donor group, and postoperative ventila-
tion and gas exchange were not significantly different either.
They concluded that successful outcomes can be achieved
with the use of extended donor lungs. Unfortunately, they
did not report the distribution of recipient diagnosis in their
article but do suggest that extended donor lungs should be
used primarily in recipients with emphysema.
In this study we have applied the same criteria to identify
marginal donor lungs as were used by the Washington
University group. Obviously, it is difficult or impossible to
quantify chest radiographic infiltrates or purulent secretions.
That is unfortunate because we believe that these 2 criteria
are very important in determining whether a marginal donor
will provide a good graft. It is our impression that the most
difficult judgment decisions pertain to the chest radiograph,
the bronchoscopic findings, and the intraoperative assess-
ment of the donor lung by means of direct inspection and
palpation. The experience of the retrieval surgeon is critical
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to a good outcome when using extended donor lungs.
During the span of this study period, we began to use lungs
with bilateral interstitial edema on radiographs and localized
areas of purulent secretions. On one occasion, a left lower
lobe pneumonia was excised by means of lobectomy, and
only the left upper lobe was transplanted on that side into the
recipient, who subsequently did well. On the contrary,
patient 15, who died, received lungs from a donor with bilat-
eral infiltrates, purulent secretions, and a significant blood
transfusion caused by trauma. This situation clearly repre-
sents an extension beyond the limits of extended.
Bhorade and colleagues6 from Loyola University
Medical Center reported their experience with extended
donor lungs in 2000. Their criteria for extended donors
were slightly different from ours and were as follows: age
greater than 55 years, smoking greater than 20 pack-years,
presence of chest radiographic infiltrate, donor ventilator
time of greater than 5 days, or donor use of inhaled drugs
(cocaine or marijuana). There were no purulent broncho-
scopic secretions, and all donors had PO2 values of greater
than 350 mm Hg. Most of their extended donors were
defined as such because of a smoking history or the use of
cocaine or marijuana. Only 7 donors were ventilated for
more than 5 days, and only 5 donors had radiographic infil-
trates, most of which were believed to be atelectasis. They
reported on a total of 113 lung transplants, 52 of which
were from extended donors, for an extended donor rate of
46%. The hospital mortality for standard donors was 20%,
and that for extended donors was 12%, which was not sig-
nificantly different. They concluded that liberalization of
donor criteria does not affect outcome after lung transplan-
tation. In their study the factor that seems to have the great-
est effect on mortality is a donor ventilation time of greater
than 5 days, but only 13% of their extended donors were in
this subgroup.
Since our program began in 1983, we have performed
more than 400 lung transplants, with an overall 30-day mor-
tality of 9%, and 12% of those patients were over the age of
60 years. As our program evolved, we began extending the
indications for lung transplantation and accepting patients
that did not meet the guidelines proposed by the
International Society for Heart and Lung Transplantation
(ISHLT) in 1998.8 Our 30-day mortality compares favor-
ably with that of other large and experienced lung transplant
programs. Harringer and colleagues10 from Hannover,
Germany, reported their 10-year experience, with a 90-day
mortality of 14%, and Meyers and coworkers9 reported the
St Louis 10-year experience, with an early hospital mortal-
ity of 8%. In fact, in their 10-year overall review, the St
Louis extended donor use rate dropped to 26% compared
with 33% in their study cohort from 1995.
From the cohort (n = 128) included in this study, 29% are
nonguideline recipients, as defined by the ISHLT8; that is,
they are older (n = 19 [15%]) than the guidelines would rec-
ommend or are colonized with B cepacia (n = 14 [11%]).
Our other nonguideline recipients had transplants that
required concurrent aorta-coronary bypass, combined liver-
lung transplant, or single lung transplantation for bron-
choalveolar carcinoma after previous pneumonectomy and
wedge resections. One case involved a retransplant for
chronic rejection in a patient with cystic fibrosis. Early mor-
tality with these nonguideline recipients did not seem to be
increased, at least when standard donors were used (Table
6). There seems to be room to further extend recipient selec-
tion criteria, but care needs to be taken not to place organs
from truly extended donors into high-risk recipients. Late
outcomes with nonguideline recipients need to be evaluated
in the future as our experience with this group increases.
Currently, our program performs primarily bilateral lung
transplantations. Eighty-four percent of the transplants in
the study cohort were bilateral lung transplants, and the
conclusions should probably be restricted to this group of
recipients. Moreover, only 1 patient with a single lung
transplant died early, and there were only 3 heart-lung
transplants, all of which were in the standard donor group.
In this study we found that the use of extended donor
lungs at a rate of 51% was associated with a significant
increase in early mortality at both 30 and 90 days after lung
transplant. Most of the deaths occurred within 30 days.
Early 30-day mortality was 6.2% in the standard donor
group and increased to 17.5% in the extended donor group.
We do believe that extending the criteria for lung donation
is justified and safe; however, the limits are difficult to
define, particularly with respect to subjective indexes such
as the chest radiographic and the bronchoscopic findings. It
may be that a marginal donor rate of 51% is too high, espe-
cially with certain higher risk recipients.
Theoretically, an aggressive policy of donor assessment
and use should result in a decrease in waiting time on the
list and decreased deaths on the waiting list. It may also
allow for expansion of recipient criteria. However, it does
not seem ethically justified to use an extended donor if the
waiting list is short or if the patients are not rapidly deteri-
orating on the list. If a transplant program has a fairly large
donor pool, then this may be the case; however, for most
TABLE 9. Deaths with extended criteria per extended crite-
ria
Criteria Proportion
Smoking >20 pack-years 2/26 (8%)
Age >55 y 1/9 (11%)
Abnormal chest radiograph 8/41 (20%)
Purulent bronchoscopic findings 3/8 (38%)
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programs, the waiting list is long and the donor pool is
small, limited, or both. In this situation it seems justified to
use an extended donor lung in certain circumstances.
What defines extended is a weakness of the currently
accepted criteria. Most extended donor lungs will function
well. Unilateral infiltrates, basal or dependent atelectasis,
and mucoid secretions suctioned out completely almost
always result in good graft function. Identification of these
particular situations depends on the clinical experience of
the retrieval surgeon and hands-on inspection in the donor
operating room. Donor age by itself has also not been a
problem in our experience and, in our opinion, is a less
important criterion.
Most worrisome are the bilateral infiltrates or truly puru-
lent secretions. Although the majority of extended donor
lungs will function adequately, it is this subgroup that
seems to have the highest risk of death (Table 8). We exam-
ined the number of deaths with an extended criteria per
extended criteria to get some numeric sense of the risk con-
tained in each criteria (Table 9). Admittedly, a multivariate
regression with each donor criteria as an independent vari-
able would be the most powerful analysis. Unfortunately,
because of the small number of deaths, which is more
important than the total number of patients, we were unable
to examine this rigorously. However, purulent secretions on
bronchoscopy and an abnormal chest radiograph seem to
predict mortality.
Currently, we continue to use extended donor lungs but
not those with bilateral infiltrates or truly purulent secre-
tions. We strongly favor standard donors for single lung
transplantation, heart-lung transplantation, and other com-
plex or redo cases. We also favor standard donors for recip-
ients with pulmonary hypertension, pulmonary fibrosis with
secondary pulmonary hypertension, and cystic fibrosis with
B cepacia colonization. The increased mortality with B
cepacia is well recognized,11 but whether early extubation
and movement out of the ICU will reduce this is not known.
Our recipients seem relatively evenly matched in the 2
groups with respect to age and underlying diagnosis; how-
ever, there were significantly more female subjects in the
extended donor group. It is unclear why this is the case.
Perhaps because of smaller absolute lung size in female sub-
jects, we were more likely to use an extended donor for fear
that another donor of appropriate size would not come along
soon enough, especially in rapidly deteriorating patients.
Ultimately, the balance of male to female subjects is even
when looking at the mortality in each group (Table 7 and 8).
In summary, many extended donor lungs will result in a
good outcome after transplantation; however, extended
donor use can result in increased early mortality compared
with that with standard or ideal donors. Extended donors
should be assessed by an experienced lung transplant sur-
geon, particularly if plans exist to use that lung in a higher
risk recipient. Donors with bilateral infiltrates not related to
atelectasis, frankly purulent secretions, or both, should be
used with extreme caution. Extended donor age and smok-
ing history do not seem to affect early outcome but may
play a role in late functional results. Further work is needed
to define the limits for extended donors, and these limits
may change as lung preservation techniques are improved.
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Discussion
Dr Michael S. Mulligan (Seattle, Wash). Toronto has long
been a source of innovative and significant contributions. It is a
privilege to comment on this article. Your very credible skepticism
is both timely and important.
I have several questions. First, as you stated, several reports
have suggested equivalent outcomes when standard and marginal
donors are used. As background for the audience, these series
include the 1993 University of Virginia report (although their def-
inition of marginal was more conservative, with a PO2 of up to 350
mm Hg and ventilator time of less than 2 days), the 1995
Washington University report (perhaps the largest series, which
was later commented on by Dr Patterson at the 1999 meeting of
the American Surgical Association), the 1999 Australian series
(which used the same criteria as you did but also included patients
who had yeast on their Gram stain), and finally, the 2000 Loyola
series, which defined a marginal PO2 as less than 350 mm Hg.
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Obviously, differences in chest radiographic and bronchoscopic
findings are difficult to standardize among series. Lessons learned
from one series cannot necessarily be applied to another.
Furthermore, no consistent use of marginal donors in recipients with
a particular diagnosis could be defined, but most avoided marginal
donors for single lung transplants in primary pulmonary hyperten-
sion and strongly recommended the use of these donors in emphyse-
matous recipients. Do you think your use in recipients with primary
pulmonary hypertension, patients with cystic fibrosis with B Cepacia
colonization, and even in reduced lung transplants explained your
increased mortality in the extended or marginal group?
Second, given that reperfusion injury and acute dysfunction
increase major histocompatibility complex II antigen expression
and thereby possibly increase susceptibility to acute rejection and
obliterative bronchiolitis, do you think that 30-day or even 1-year
follow-up is adequate?
Third, in your series only one lung recipient died. Your policy
favors double lung transplants. Some argue that with one marginal
lung, a double lung is preferred. Others believe that with a single
transplant, at least one lung is not vulnerable to reperfusion injury.
Can you comment on the use of marginal donors with specific
regard to single and double lung transplants?
Finally, in your report and in the series from Barnes Hospital,
donor treatment with high-dose methylprednisolone (Solu-
Medrol) is recommended. Are you aware of any data that demon-
strate a beneficial effect of this practice?
Dr Bryan F. Meyers (St Louis, Mo). We have just recently
reviewed 550 transplants at Washington University in St Louis and
cannot demonstrate that using a marginal donor is an increased
risk factor on the basis of survival or the development of acute
rejection or bronchiolitis obliterans. I know that the University of
Toronto has prior experience with marginal donors that was favor-
able, and I wonder if you looked at the possibility that this is just
a bad run and a statistical aberration in a small number of patients.
I noticed that you had an increased number of female donors.
Female recipients and certain underlying recipient diagnoses are
independent risk factors for early mortality on the basis of the
ISHLT database. Do you think it might just be a fluke?
Dr Pierre. I will first address the issue about the female
recipients. Female recipients in the ISHLT database are protec-
tive. They have a lower 1-year mortality than male recipients.
Why we have more female recipients in our extended recipient
group and why that group should have a higher mortality is hard
to explain. I tried to address that somewhat, but I do not have a
good explanation.
Dr Mulligan, you outlined a number of the previous studies that
looked at marginal donor lungs, and I think an explanation as to how
our donors and recipients differ would take some time, but your spe-
cific questions about the use of extended or marginal donor lungs in
higher risk recipients is, I think, very important. My own belief is
that I do not think we should be using these lungs in patients with B
cepacia. I do not know that I can prove that getting the patients extu-
bated and out of the ICU earlier will reduce the incidence of B cepa-
cia infection or mortality from B cepacia, but patients with B
cepacia do seem to represent a fair number of the deaths in this
series. Therefore, I do think that patients with pulmonary hyperten-
sion, redo patients, and other difficult or complicated cases in which
high risk might be expected in the perioperative period should prob-
ably also receive standard donor lungs or donor lungs that do not
have marginal or extended criteria, such as bilateral infiltrates, or
any question about the bronchoscopy.
In terms of long-term follow-up, I agree that this is a short-term
study looking at 30-day or 90-day mortality. Long-term data will
be very important to look at the outcome with respect to extended
or marginal donor lungs, particularly when it comes to the other
extended criteria, such as advanced donor age or smoking history,
and the risk of malignancy will also become an issue.
As far as single lungs go, we do favor using marginal donor
lungs in bilateral lung transplantation and avoid them in the use of
single lungs. The one patient who died did receive a marginal
donor lung for a single lung transplant; the donor lung was mar-
ginal because of an infiltrate and a contusion on the left side, and
it was the right side that was transplanted. However, that patient
obviously did not do well.
Regarding the use of methoprednisolone, there are not a lot of
data supporting that. There is one report from Sacramento looking
at the retrieval of organs after the administration of methopred-
nisolone, suggesting that the overall yield in retrieval was
increased by the use of preoperative methoprednisolone to the
donor.
